New study tracks safety of ultomiris in pregnant women

NCT ID NCT06312644

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 75 pregnant women who have taken Ultomiris (ravulizumab) for conditions like PNH or aHUS. Researchers will track pregnancy outcomes and baby health up to one year after birth. The goal is to gather safety information, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Ultomiris (ravulizumab)

What this could lead to

If successful, this study could provide important safety data on using Ultomiris during pregnancy, helping doctors and patients make informed decisions.

What could go wrong

This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be limited by the small number of participants (75) and lack of a comparison group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atypical hemolytic-uremic syndrome Hemoglobinuria, Paroxysmal myasthenia gravis neuromyelitis optica paroxysmal nocturnal hemoglobinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Boston, Massachusetts, 02210, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Research Site

    NOT_YET_RECRUITING

    Melbourne, Victoria, 3050, Australia

    Contact

  • Research Site

    RECRUITING

    Paris, 75475, France

    Contact

  • Research Site

    RECRUITING

    Essen, Norte-Westfalia, D-45147, Germany

    Contact

  • Research Site

    RECRUITING

    Rome, 00168, Italy

    Contact

  • Research Site

    ACTIVE_NOT_RECRUITING

    Seoul, South Korea

  • Research Site

    ACTIVE_NOT_RECRUITING

    London, SE5 9NU, United Kingdom